Last reviewed · How we verify
Lipiodol UltraFluid
Lipiodol UltraFluid is an iodized poppy seed oil contrast agent that accumulates in hepatic lesions and provides both diagnostic imaging and therapeutic embolization.
Lipiodol UltraFluid is an iodized poppy seed oil contrast agent that accumulates in hepatic lesions and provides both diagnostic imaging and therapeutic embolization. Used for Hepatocellular carcinoma (diagnostic imaging and transarterial chemoembolization), Diagnostic imaging of liver lesions.
At a glance
| Generic name | Lipiodol UltraFluid |
|---|---|
| Also known as | Oil-based contrast |
| Sponsor | Amsterdam UMC, location VUmc |
| Drug class | Iodized contrast agent / embolic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Lipiodol UltraFluid is a lipophilic contrast medium composed of iodized poppy seed oil that preferentially accumulates in hepatocellular carcinoma and other liver tumors due to their increased vascularity and the Kupffer cell uptake mechanism. It is used both as a diagnostic imaging agent for detecting liver lesions and as a therapeutic embolic agent in transarterial chemoembolization (TACE) procedures, where it delivers chemotherapy directly to tumor vasculature while occluding blood supply.
Approved indications
- Hepatocellular carcinoma (diagnostic imaging and transarterial chemoembolization)
- Diagnostic imaging of liver lesions
Common side effects
- Transient fever
- Abdominal pain
- Nausea
- Hepatic dysfunction
Key clinical trials
- Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients (NA)
- Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2) (PHASE2)
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC (NA)
- Achilles Tendinopathy Embolization (PHASE1)
- Phase II Trial of Lung Chemoemobolization (PHASE2)
- MANDARIN (S6371) (PHASE3)
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
- Lateral Plantar Artery Embolization For Plantar Fasciitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipiodol UltraFluid CI brief — competitive landscape report
- Lipiodol UltraFluid updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI